Large-scale vaccination strategies are currently being deployed against severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2). Whether systemic medication for skin diseases affects the efficacy of vaccination and whether temporary interruption or extension of the dosing interval is necessary is under debate. Most immunomodulating/immunosuppressive drugs only affect vaccine-induced immune responses to a limited or moderate extent, preserving sufficient immunity in most patients. Mycophenolate mofetil, Janus kinase inhibitors, and rituximab require a more cautious approach, and judicious timing of vaccination might be appropriate in patients receiving these treatments. It should be noted that, for most drugs except methotrexate, data on the length of the interruption period to restore vaccine-induced immune responses to normal levels are either very limited or absent. In these cases, only the drug half-life can be used as a practical guideline. In most patients, systemic medication can be continued through the vaccination process, although case-by-case decisions can be considered.

目前正在部署针对严重急性呼吸综合征冠状病毒-2 (SARS-Cov-2) 的大规模疫苗接种策略。皮肤病的全身用药是否会影响疫苗接种的效果以及是否需要暂时中断或延长给药间隔仍存在争议。大多数免疫调节/免疫抑制药物仅在有限或中等程度上影响疫苗诱导的免疫反应，从而使大多数患者保持足够的免疫力。吗替麦考酚酯、Janus 激酶抑制剂和利妥昔单抗需要更加谨慎的方法，并且明智的疫苗接种时机可能适合接受这些治疗的患者。应该指出的是，对于除甲氨蝶呤以外的大多数药物，有关将疫苗诱导的免疫反应恢复到正常水平的中断期长度的数据非常有限或缺乏。在这些情况下，只有药物半衰期可以用作实用指南。对于大多数患者，可以在疫苗接种过程中继续全身用药，但可以考虑具体情况而定。